Skip to main content
Fig. 9 | Alzheimer's Research & Therapy

Fig. 9

From: Metabolic phenotyping reveals a reduction in the bioavailability of serotonin and kynurenine pathway metabolites in both the urine and serum of individuals living with Alzheimer’s disease

Fig. 9

Tryptophan pathway. Pathway map presenting the key metabolites that reported significant inter-group differences following Kruskal-Wallis tests. Post hoc Dunn tests revealed that those highlighted with red shading were significantly lower in the AD group in serum, whilst those highlighted with blue shading were significantly lower in AD in urine. The downstream metabolites are inherently more polar and are therefore fit with biological and metabolic logic that polar, downstream metabolites would be renally excreted and therefore altered in urine

Back to article page

Alzheimer's Research & Therapy

ISSN: 1758-9193